AAH promotes Chambers to chief commercial officer

Date:

Share post:

AAH Pharmaceuticals (AAH) has announced the appointment of Brian Chambers as chief commercial officer.

“I’m proud to lead the commercial functions in AAH in my new role and broader area of responsibility,” said Brian, adding: “I’m committed to delivering on great value for our customers and building and strengthening our supplier partnerships.”

Brian has been associated with AAH Pharmaceuticals for more than 14 years. He joined the company as Business Development manager in October 2008. His previous role in the organization was on Sales and Marketing as director.

He posted on LinkedIn: “This is a big move for me personally, but that’s a side hustle. What is the main play here is AAH becoming a standalone independent wholesale business focused on only the AAH customer and our core business and this is just one part of that.

“The pharmacy network is changing and I’m committed to ensuring AAH is more relevant than ever. I couldn’t be more grateful for some of the comments of support here, thank you, it genuinely means a lot.”

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Current Issue June 2023

Related articles

MHRA grants authorisation for LEO Pharma’s Adtralza 2 mL pen solution

The Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the marketing authorisation of Adtralza, a dermatological solution...

Grundon launches maiden UK-wide inhaler recycling programme

Grundon Waste Management has introduced what it claims to be the UK's first verified nationwide inhaler return and...

‘Record fine imposed on hydrocortisone manufacturers for dominant position abuse and 10,000% price increase’

The Competition Appeal Tribunal (CAT) has upheld the Competition and Markets Authority’s (CMA) findings against two pharmaceutical manufacturers...

Vision Report: Legal reforms, adequate funding imperative for success of community pharmacy

Achieving the community pharmacy vision necessitates legal adjustments and additional funding beyond recent boosts, the pharmacy vision document...